Article Figures & Data
Tables
- TABLE 1
Main reports on Pneumocystis pneumonia treatment using caspofungin
Author(s) (reference), yr of publication Patient status (no. of patients)b Regimena Treatment efficacy or failure Beltz et al. (5), 2006 ALL (1) CAS and SMX-TMP Efficacy Zhang et al. (6), 2006 COPD (1) CAS and SMX-TMP Efficacy Annaloro et al. (7), 2006 BMTR (1) CAS and SMX-TMP Efficacy Utili et al. (8), 2007 RTR (4) CAS and SMX-TMP Efficacy Mu et al. (9), 2009 CML (1) CAS and SMX-TMP Efficacy Ceballos et al. (10), 2011 HIV infection (1) CAS and SMX-TMP Efficacy Armstrong-James et al. (11), 2011 HIV infection (4) CAS and SMX-TMP Efficacy Tu et al. (12), 2013 RTR (3) CAS and SMX-TMP Efficacy Lee et al. (13), 2016 HIV (1) CAS and SMX-TMP Efficacy Lu et al. (14), 2017 HTR (1) CAS and SMX-TMP Efficacy Zhang et al. (15), 2018 Non-HIV immunosuppression (14) CAS and SMX-TMP Efficacy Koshi et al. (16), 2019 Sjogren’s syndrome (1) CAS and SMX-TMP Efficacy Hof and Schnülle (18), 2008 Wegener’s disease (1) CAS Efficacy Lee et al. (19), 2017 HIV infection (1) CASc Efficacy Huang et al. (20), 2018 Autoimmune diseases (2) CASc Efficacy Huang et al. (21), 2019 HIV infection (7) CASc Efficacy/failured Kamboj et al. (22), 2006 Cancer (2) CAS Failure Kim et al. (23), 2013 HIV-infection (4) CAS Failure ↵a CAS and SMX-TMP, caspofungin and sulfamethoxazole-trimethoprim combination; CAS, caspofungin.
↵b ALL, Acute lymphoblastic leukemia; COPD, chronic obstructive pulmonary disease; RTR renal transplant recipient; CML, chronic myelomonocytic leukemia; HIV, human immunodeficiency virus; HRT, heart transplant recipient; BMTR, bone marrow transplant recipient.
↵c CAS as second-line treatment.
↵d Efficacy, 4 out of 7 cases.